Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||ATP128 + BI 754091|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ATP128||ATP128 is a chimeric protein vaccine that potentially modify antigen presentation of dendritic cells, leading to activation of immune response against tumor cells (NCI Drug Dictionary).|
|BI 754091||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 62||BI 754091 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol. 36, no. 5_suppl (February 2018) 212-212).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04046445||Phase Ib/II||ATP128 + BI 754091 ATP128||Phase 1b Study to Evaluate ATP128, With or Without BI 754091, in Patients With Stage IV Colorectal Cancer (KISIMA-01)||Recruiting|